Chris Schott
Chris Schott
lack patent portfolio top
It is our top pick. I like the lack of patent expirations... They have a portfolio of new products.
lack patent portfolio top
It is our top pick. I like the lack of patent expirations...They have a portfolio of new products.
addressing concerns december direction following increase sign step view
We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.
catalyst critical event positive potential view
We view this as a critical event in the Pfizer story and a potential positive catalyst for the stock.